-+ 0.00%
-+ 0.00%
-+ 0.00%

Maze net loss narrows to $24.2 million in Q1 FY26; revenue swings to $20 million

PUBT·05/12/2026 20:02:06
Listen to the news
Maze net loss narrows to $24.2 million in Q1 FY26; revenue swings to $20 million
  • Maze Therapeutics posted a narrower net loss of USD 24.2 million, or USD 0.45 per share, for quarter ended March 31, 2026.
  • Revenue swung to USD 20 million from no revenue a year earlier, tied to a Shionogi milestone under the MZE001 license.
  • R&D expense climbed to USD 34.1 million, while G&A expense rose to USD 12.4 million.
  • Cash, cash equivalents, marketable securities totaled USD 362.9 million at March 31, 2026; cash runway expected to extend into 2029 including April 2026 net proceeds from a USD 150 million registered offering and a USD 20 million milestone payment.
  • Reported positive Phase 2 HORIZON topline data for MZE829 in broad AMKD, showing a 35.6% mean uACR reduction at week 12; plans pivotal trial initiation in first half of 2027, subject to regulatory feedback.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605121601PRIMZONEFULLFEED9718774) on May 12, 2026, and is solely responsible for the information contained therein.